• Je něco špatně v tomto záznamu ?

In silico and in vitro evaluation of imatinib as an inhibitor for SARS-CoV-2

N. Mulgaonkar, H. Wang, S. Mallawarachchi, D. Růžek, B. Martina, S. Fernando

. 2023 ; 41 (7) : 3052-3061. [pub] 20220226

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010610

The rapid geographic expansion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious agent of Coronavirus Disease 2019 (COVID-19) pandemic, poses an immediate need for potent drugs. Enveloped viruses infect the host cell by cellular membrane fusion, a crucial mechanism required for virus replication. The SARS-CoV-2 spike glycoprotein, due to its primary interaction with the human angiotensin-converting enzyme 2 (ACE2) cell-surface receptor, is considered a potential target for drug development. In this study, around 5,800 molecules were virtually screened using molecular docking. Five molecules were selected for in vitro experiments from those that reported docking scores lower than -6 kcal/mol. Imatinib, a Bcr-Abl tyrosine kinase inhibitor, showed maximum antiviral activity in Vero cells. We further investigated the interaction of imatinib, a compound under clinical trials for the treatment of COVID-19, with SARS-CoV-2 RBD, using in silico methods. Molecular dynamics simulations verified that imatinib interacts with RBD residues that are critical for ACE2 binding. This study also provides significant molecular insights on potential repurposable small-molecule drugs and chemical scaffolds for the development of novel drugs targeting the SARS-CoV-2 spike RBD.Communicated by Ramaswamy H. Sarma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010610
003      
CZ-PrNML
005      
20230801132532.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/07391102.2022.2045221 $2 doi
035    __
$a (PubMed)35220926
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mulgaonkar, Nirmitee $u Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX, USA $1 https://orcid.org/0000000346078391
245    10
$a In silico and in vitro evaluation of imatinib as an inhibitor for SARS-CoV-2 / $c N. Mulgaonkar, H. Wang, S. Mallawarachchi, D. Růžek, B. Martina, S. Fernando
520    9_
$a The rapid geographic expansion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious agent of Coronavirus Disease 2019 (COVID-19) pandemic, poses an immediate need for potent drugs. Enveloped viruses infect the host cell by cellular membrane fusion, a crucial mechanism required for virus replication. The SARS-CoV-2 spike glycoprotein, due to its primary interaction with the human angiotensin-converting enzyme 2 (ACE2) cell-surface receptor, is considered a potential target for drug development. In this study, around 5,800 molecules were virtually screened using molecular docking. Five molecules were selected for in vitro experiments from those that reported docking scores lower than -6 kcal/mol. Imatinib, a Bcr-Abl tyrosine kinase inhibitor, showed maximum antiviral activity in Vero cells. We further investigated the interaction of imatinib, a compound under clinical trials for the treatment of COVID-19, with SARS-CoV-2 RBD, using in silico methods. Molecular dynamics simulations verified that imatinib interacts with RBD residues that are critical for ACE2 binding. This study also provides significant molecular insights on potential repurposable small-molecule drugs and chemical scaffolds for the development of novel drugs targeting the SARS-CoV-2 spike RBD.Communicated by Ramaswamy H. Sarma.
650    _2
$a zvířata $7 D000818
650    _2
$a Cercopithecus aethiops $7 D002522
650    _2
$a lidé $7 D006801
650    12
$a SARS-CoV-2 $7 D000086402
650    12
$a COVID-19 $7 D000086382
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a angiotensin-konvertující enzym 2 $7 D000085962
650    _2
$a imatinib mesylát $7 D000068877
650    _2
$a Vero buňky $7 D014709
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wang, Haoqi $u Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX, USA $1 https://orcid.org/0000000258375847
700    1_
$a Mallawarachchi, Samavath $u Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX, USA $1 https://orcid.org/0000000281532388
700    1_
$a Růžek, Daniel $u Veterinary Research Institute, Brno, and Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic $1 https://orcid.org/0000000346552380 $7 stk2008441707
700    1_
$a Martina, Byron $u Artemis One Health Research Institute, Delft, The Netherlands $1 https://orcid.org/0000000349804619
700    1_
$a Fernando, Sandun $u Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX, USA $1 https://orcid.org/0000000276922170
773    0_
$w MED00002554 $t Journal of biomolecular structure & dynamics $x 1538-0254 $g Roč. 41, č. 7 (2023), s. 3052-3061
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35220926 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132529 $b ABA008
999    __
$a ok $b bmc $g 1963196 $s 1196875
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 7 $d 3052-3061 $e 20220226 $i 1538-0254 $m Journal of biomolecular structure & dynamics $n J Biomol Struct Dyn $x MED00002554
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace